IL17A and irritable bowel syndrome: Fs.Cr was found to regulate several additional key molecules involved in IBD, reducing the levels of TNF-α, IFN-γ, MDA and MPO, and increasing IL-17 SOD, GPX, CAT, and total GSH, thus demonstrating their role in decreasing UC severity by reducing oxidative damage, inflammation, and promoting mucosal repair 451.